
Hangzhou RuiPu Genetic Technology Co., Ltd. utilizes cutting-edge technology platforms, a leading diverse expert team, and four independently developed core technologies to cover precision diagnostics in oncology, genetic screening in health checks, and large health data management.
Domestic enterprises initiate the signing of the 'Quality Review Agreement' by overseas individuals to ensure the authority and credibility of test document information and obtain full authorization.
Domestic enterprises initiate signing through eSignGlobal, and overseas inspectors or experts review medical document information, sign, and complete agreement confirmation after verification.
Signing through overseas cooperation strengthens the authority of medical services and report security.






